Davis Polk & Wardwell has won the lead role on a $43.7bn (£21.9bn) biotech takeover bid, as Swiss healthcare group Roche offers to buy the remaining shares in US biotech company Genentech. Roche already owns 55.9% on Genentech, and the deal to purchase the remaining 44.1% would form the seventh-largest drug maker in the US, with sales of $15bn (£7.5bn) in the country, according to Roche.
July 22, 2008 at 11:51 AM
1 minute read
The original version of this story was published on Legalweek
Davis Polk & Wardwell has won the lead role on a $43.7bn (£21.9bn) biotech takeover bid, as Swiss healthcare group Roche offers to buy the remaining shares in US biotech company Genentech.
Roche already owns 55.9% on Genentech, and the deal to purchase the remaining 44.1% would form the seventh-largest drug maker in the US, with sales of $15bn (£7.5bn) in the country, according to Roche.
Presented by BigVoodoo
Celebrate outstanding achievement in law firms, chambers, in-house legal departments and alternative business structures.
The African Legal Awards recognise exceptional achievement within Africa s legal community during a period of rapid change.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
